Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).

Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK.

Am J Gastroenterol. 2011 Feb;106(2):307-16. doi: 10.1038/ajg.2010.455. Epub 2010 Dec 14.

PMID:
21157444
2.

Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.

Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R.

Hepatology. 2007 Mar;45(3):549-59.

PMID:
17326150
3.

Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial.

Sharma K, Pant S, Misra S, Dwivedi M, Misra A, Narang S, Tewari R, Bhadoria AS.

Saudi J Gastroenterol. 2014 Jul-Aug;20(4):225-32. doi: 10.4103/1319-3767.136975.

4.

Editorial: rifaximin and minimal hepatic encephalopathy.

Butterworth RF.

Am J Gastroenterol. 2011 Feb;106(2):317-8. doi: 10.1038/ajg.2010.460.

PMID:
21301455
5.

Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.

Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ.

Gastroenterology. 2011 Feb;140(2):478-487.e1. doi: 10.1053/j.gastro.2010.08.061. Epub 2010 Sep 21.

6.

Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.

Sidhu SS, Goyal O, Parker RA, Kishore H, Sood A.

Liver Int. 2016 Mar;36(3):378-85. doi: 10.1111/liv.12921. Epub 2015 Aug 17.

PMID:
26201713
7.

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.

Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP.

Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. doi: 10.1111/j.1365-2036.2011.04808.x. Epub 2011 Aug 17.

8.

A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.

Mittal VV, Sharma BC, Sharma P, Sarin SK.

Eur J Gastroenterol Hepatol. 2011 Aug;23(8):725-32. doi: 10.1097/MEG.0b013e32834696f5.

PMID:
21646910
9.

Rifaximin treatment in hepatic encephalopathy.

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP.

N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.

10.

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK.

Am J Gastroenterol. 2013 Sep;108(9):1458-63. doi: 10.1038/ajg.2013.219. Epub 2013 Jul 23.

PMID:
23877348
11.

Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.

Ahluwalia V, Wade JB, Heuman DM, Hammeke TA, Sanyal AJ, Sterling RK, Stravitz RT, Luketic V, Siddiqui MS, Puri P, Fuchs M, Lennon MJ, Kraft KA, Gilles H, White MB, Noble NA, Bajaj JS.

Metab Brain Dis. 2014 Dec;29(4):1017-25. doi: 10.1007/s11011-014-9507-6. Epub 2014 Mar 4.

12.

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM.

PLoS One. 2013;8(4):e60042. doi: 10.1371/journal.pone.0060042. Epub 2013 Apr 2.

13.

Treatment with a potassium-iron-phosphate-citrate complex improves PSE scores and quality of life in patients with minimal hepatic encephalopathy: a multicenter, randomized, placebo-controlled, double-blind clinical trial.

Burkard T, Biedermann A, Herold C, Dietlein M, Rauch M, Diefenbach M.

Eur J Gastroenterol Hepatol. 2013 Mar;25(3):352-8. doi: 10.1097/MEG.0b013e32835afaa5.

PMID:
23117470
14.

Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis.

Ahluwalia V, Wade JB, Thacker L, Kraft KA, Sterling RK, Stravitz RT, Fuchs M, Bouneva I, Puri P, Luketic V, Sanyal AJ, Gilles H, Heuman DM, Bajaj JS.

J Hepatol. 2013 Sep;59(3):467-73. doi: 10.1016/j.jhep.2013.04.023. Epub 2013 May 7.

15.
16.

Rifaximin therapy in minimal hepatic encephalopathy cirrhotics.

Zullo A, Hassan C, Lorenzetti R.

Am J Gastroenterol. 2011 Nov;106(11):2041; author reply 2041-2. doi: 10.1038/ajg.2011.216. No abstract available.

PMID:
22056578
17.

Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.

Zhang Y, Feng Y, Cao B, Tian Q.

Int J Clin Exp Med. 2015 Feb 15;8(2):2954-7. eCollection 2015.

18.

Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.

Prakash RK, Kanna S, Mullen KD.

Clin Ther. 2013 Sep;35(9):1458-73. doi: 10.1016/j.clinthera.2013.07.421. Epub 2013 Aug 22. Review.

PMID:
23972578
19.

Lactulose for minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction.

Sharma P, Sharma BC.

Saudi J Gastroenterol. 2012 May-Jun;18(3):168-72. doi: 10.4103/1319-3767.96448.

20.

Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.

Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM.

Hepatology. 2012 Apr;55(4):1164-71. doi: 10.1002/hep.25507.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk